KCG Holdings Inc. boosted its position in shares of Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) by 259.0% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 105,409 shares of the biotechnology company’s stock after buying an additional 76,046 shares during the period. KCG Holdings Inc. owned about 0.91% of Ritter Pharmaceuticals worth $150,000 at the end of the most recent reporting period.
Ritter Pharmaceuticals, Inc. (NASDAQ RTTR) opened at 0.60 on Friday. Ritter Pharmaceuticals, Inc. has a 12 month low of $0.50 and a 12 month high of $3.75. The firm’s market capitalization is $8.85 million. The stock’s 50 day moving average price is $0.57 and its 200-day moving average price is $1.33.
Ritter Pharmaceuticals (NASDAQ:RTTR) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). Equities analysts forecast that Ritter Pharmaceuticals, Inc. will post ($0.42) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “KCG Holdings Inc. Acquires 76,046 Shares of Ritter Pharmaceuticals, Inc. (RTTR)” was published by BNB Daily and is the property of of BNB Daily. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://www.baseball-news-blog.com/2017/08/19/kcg-holdings-inc-raises-position-in-ritter-pharmaceuticals-inc-rttr-updated.html.
A number of brokerages recently issued reports on RTTR. Zacks Investment Research upgraded Ritter Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a report on Thursday, August 10th. Chardan Capital lowered their price target on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating for the company in a report on Tuesday, August 8th. Finally, Maxim Group reiterated a “hold” rating on shares of Ritter Pharmaceuticals in a report on Friday, August 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Ritter Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $4.88.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.